详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: A randomized clinical trial

文献详情

资源类型：

作者：

机构： [a]Innovation Center for Neurological Disorders, Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China [b]Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China [c]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China [d]Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China [e]National Clinical Research Center for Geriatric Disorders, Beijing, China [f]Department of Gerontology, Fuxing Hospital, Capital Medical University, Beijing, China [g]Department of Health Statistics, Second Military Medical University, Shanghai, China [h]Department of Neurology, Daqing Oilfield General Hospital, China [i]Department of Neurology, Henry Ford Hospital, Detroit, MI, USA [j]Centre for Studies in Aging, McGill University, Montreal, QC, Canada

出处：

DOI：

ISSN：

关键词： Clinical trial Compound Chinese medicine SaiLuoTong/SLT Vascular dementia

摘要：

Introduction: No licensed medications are available to treat vascular dementia (VaD). Methods: Patients were randomly assigned to experimental groups (SaiLuoTong [SLT] 360 or 240 mg for groups A and B for 52 weeks, respectively) or placebo group (SLT 360 mg and 240 mg for group C only from weeks 27 to 52, respectively). Results: Three hundred twenty-five patients were included in final analysis. At week 26, the difference in VaD Assessment Scale–cognitive subscale scores was 2.67 (95% confidence interval, 1.54 to 3.81) for groups A versus C, and 2.48 (1.34 to 3.62) for groups B versus C (both P <.0001). However, at week 52, no difference was observed among the groups on the VaD Assessment Scale–cognitive subscale (P =.062) because of the emerging efficacy of SLT in placebo beginning at week 27. Discussion: This study suggests that SLT is effective for treatment of VaD, and this compound Chinese medicine may represent a better choice to treat VaD. © 2018 The Authors

基金：

语种：

第一作者：

第一作者机构： [a]Innovation Center for Neurological Disorders, Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China [b]Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China [c]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China [d]Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China [e]National Clinical Research Center for Geriatric Disorders, Beijing, China

通讯作者：

通讯机构： [a]Innovation Center for Neurological Disorders, Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China [b]Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China [c]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China [d]Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China [e]National Clinical Research Center for Geriatric Disorders, Beijing, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule [2]The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule [3]Rationale and Design of a Multicenter, Phase 2 Clinical Trial to Investigate the Efficacy of Traditional Chinese Medicine SaiLuoTong in Vascular Dementia [4]The efficacy of Cognitive training in patients with VAsCular Cognitive Impairment, No dEmentia (the Cog-VACCINE study): study protocol for a randomized controlled trial [5]从西医中培养中西医结合复合型临床人才的几点思考 [6]中药抗人巨细胞病毒研究进展 [7]The efficacy of Cognitive training in patients with VAsCular Cognitive Impairment, No dEmentia (the Cog-VACCINE study): study protocol for a randomized controlled trial [8]中药复方抗瘤丸优化方对U87裸鼠移植瘤动物模型作用机制研究 [9]皮层下缺血性血管性痴呆 [10]中药复方溶石剂对人体胆结石的直接溶解作用及其安全性评价